Eledon Pharmaceuticals reported that tegoprubart failed to meet superiority against tacrolimus on the primary endpoint in the Bestow Phase II kidney transplant trial but produced preservation of estimated glomerular filtration rates and a favorable safety profile. Management signaled intent to pursue later‑stage development based on efficacy signals and tolerability. The data were presented at ASN Kidney Week; Eledon emphasized the drug’s renal function outcomes and long‑term safety that could support a Phase III program despite the missed primary endpoint. The company’s shares fell sharply on the headline miss but management framed the results as a path to potential approval with a refined development plan. Nephrology stakeholders will assess whether the observed kidney‑function durability and safety will translate into clinically meaningful advantages over calcineurin inhibitors in larger, well‑controlled trials and whether payers will accept such endpoints for reimbursement.